J 2021

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis

HERMAN, Dalibor, Pavel OSMANCIK, Petr NEUZIL, Pavel HALA, Veronika LEKESOVA et. al.

Basic information

Original name

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis

Authors

HERMAN, Dalibor (203 Czech Republic), Pavel OSMANCIK (203 Czech Republic, guarantor), Petr NEUZIL (203 Czech Republic), Pavel HALA (203 Czech Republic), Veronika LEKESOVA, Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Marek HOZMAN (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Martina NOVÁČKOVÁ (203 Czech Republic, belonging to the institution), Petr WIDIMSKY (203 Czech Republic) and V. Y. REDDY

Edition

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, HOBOKEN, WILEY, 2021, 1045-3873

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.942

RIV identification code

RIV/00216224:14110/21:00123114

Organization unit

Faculty of Medicine

DOI

UT WoS

000688562000001

Keywords in English

atrial natriuretic peptide; biomarkers; brain natriuretic peptide; left atrial appendage; left atrial appendage closure

Tags

Tags

International impact, Reviewed
Změněno: 6/12/2021 09:11, Mgr. Tereza Miškechová

Abstract

V originále

Introduction The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. Methods Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. Results There were no significant differences in baseline, 6 month, and delta (delta = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for delta in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for delta in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and delta concentrations of Galectin-3 and GDF-15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.